You are here

FDA to Review Tablet Formulation of Antifungal Drug Posaconazole (Noxafil)

Approval sought for once-daily administration (Apr. 10)

The FDA has accepted a new drug application (NDA) for an investigational tablet formulation of the antifungal agent posaconazole (Noxafil, Merck).

Posaconazole is currently marketed as Noxafil Oral Suspension for prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as patients who have received hematopoietic stem-cell transplants and have graft-versus-host disease, or patients with cancers of the blood who are experiencing prolonged neutropenia as a result of chemotherapy.

Regulatory approval is being sought for once-daily administration of the posaconazole tablets (following a twice-a-day loading dose on the first day of therapy).

The safety and efficacy of posaconazole have not been established in patients younger than 13 years of age.

Source: Merck; April 10, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage